Figure 6 from Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer

Potent therapeutic effects of patient’s PBMC-derived 7 × 19 CAR-T in autologous pancreatic cancer organoids. A, Tumor mass was established in NOG-ΔMHC by subcutaneous inoculation with 1 × 10⁶ pancreatic cancer organoids. After 88 days, the established tumor mass was resected and examined for HER2 expression by IHC staining. B and C, NOG-ΔMHC mice were inoculated subcutaneously with 1 × 10⁶ pancreatic cancer organoids on day 0 and then treated with intravenous injection of 5 × 10⁶ anti-HER2 Conv. CAR-T or 7 × 19 CAR-T cells on day 10 or (left) untreated. Thereafter, the tumor size (B) and the mouse survival (C) were assessed (n = 5 each in all groups, biological replicates). **, P < 0.01; ***, P < 0.001.